Polymer nanoparticles for the intravenous delivery of anticancer drugs the checkpoints on the road from the synthesis to clinical translation

Purpose: Many polymer-based nanoparticle formulations fail before or during clinical trials. This review identifies the key checkpoints a nanocarrier must satisfy after intravenous injection — biocompatibility, drug loading/release, storage stability, biodistribution, target selectivity, cellular internalization, and biodegradability — to improve the success rate of polymer-based anticancer nanomedicines.

Hypothesis: This is a review article and does not test a single formal hypothesis. Its central premise is that rational, checkpoint-based design of polymer nanoparticles — considering toxicity, payload retention, stability, biodistribution, targeting, uptake, release, and elimination — can increase the clinical translation rate of intravenous anticancer nanotherapeutics.

Aims: Briefly review administration routes and polymer-based nanocarriers for intravenous drug delivery. - Focus on synthetic polymer nanoparticles with a lipophilic core for anticancer therapeutics. - Discuss problems encountered in clinical translation. - Define the requirements a nanocarrier should satisfy for safe and effective intravenous use. - Provide guidelines for early development of polymer-based nanotherapeutics using relevant literature case studies.

Delivery system: Carrier type: Polymer-based nanoparticles (NPs) for intravenous delivery, including polymer micelles, polymersomes, dendrimers, polymeric NPs, and polymer nanocapsules. - Size range: Generally 30–300 nm; >300 nm risks thrombosis and rapid clearance by liver/spleen; <10 nm is renally excreted. - Polymers highlighted: PEG-PLGA, PEG-poly(lactide), PEG-poly(aspartic acid), PEG-poly(glutamic acid), poly(butylcyanoacrylate), poly(isobutylcyanoacrylate), cyclodextrin-PEG conjugates, Pluronic, poly(N-2-hydroxypropyl)methacrylamide (polyHPMA), poly(lactic acid), PLGA, PCL. - Payloads: Lipophilic anticancer drugs such as paclitaxel, doxorubicin, docetaxel, cisplatin, oxaliplatin, epirubicin, camptothecin, mitoxantrone, rapamycin, trabectedin. - Targeting: Passive EPR effect and active targeting with antibodies, antibody fragments, aptamers, small molecules, folate, etc. - Key requirements: Effective drug loading, formulation stability, biocompatibility/non-toxicity, sufficient residence time, selective target accumulation, internalization and drug release, complete biodegradation/elimination.

Approach: Review of preclinical and clinical literature on polymer-based NPs for intravenous anticancer delivery. Includes marketed formulations and clinical trials, with case studies on biodistribution, cellular uptake, toxicity, drug release, and degradation. No new primary experiments are reported.

Key methods: Drug loading methods: emulsification/solvent evaporation, solvent diffusion, nanoprecipitation, salting out, syringe method. - Stability: lyophilization, storage at 4 °C, colloidal stability in physiological media. - Biocompatibility: cytotoxicity, LDH release, complement activation, cytokine/chemokine modulation, IgG/IgM induction, RBC lysis/aggregation. - Biodistribution: fluorescent labeling, ICP-MS, MRI, PET/SPECT. - Cellular uptake: flow cytometry, plate fluorescence, Coulter counter; quantification of NPs per cell. - Degradation: GPC/molecular weight decrease, TEM, Raman spectroscopy. - Drug release: Peppas model, Fick’s law-based models, in vitro/in vivo correlation.

Key results: Size: Optimum intravenous NP size is 30–300 nm; >300 nm risks thrombosis and rapid clearance; <10 nm is renally excreted. - Marketed polymer NP formulations: Genexol-PM (2007, South Korea), Transdrug (2005, USA), Zinostatin stimalamer (1994, Japan), Paclical (2015, Russian Federation). - Clinical trials: Fewer than 20 polymeric NP-based therapeutics in clinical trials. - Cytokine induction: Cationic micelles induced 13 cytokines, zwitterionic 7, neutral 3, anionic 1; cross-linking reduced cytokine release. - Cellular uptake: Positive charges promote uptake; 100 and 200 nm positively charged NPs showed the largest uptake; negatively charged NPs at least one order of magnitude lower. Uptake peaked at 2–5 h and stabilized within 24 h at a lower plateau. - Degradation: PLA microspheres may persist several months to 10 months; comb-like PCL-based NPs degraded completely by 6 days, while non-degradable PMMA NPs remained unchanged after 1 week. - In vivo vs in vitro degradation: 200 nm PLGA NPs degraded faster in vivo in liver/spleen than in vitro; 500 nm NPs showed similar liver degradation but slower spleen degradation in vivo.

Interpretation: Polymeric NPs for intravenous anticancer delivery have advanced, but clinical translation remains limited. The primary goal is to reduce drug toxicity while achieving high selective drug concentration at the target. Low toxicity of the unloaded carrier, biocompatibility, favorable biodistribution, efficient target uptake, and complete biodegradation are critical. The development process is interdisciplinary, requiring chemistry, chemical engineering, biology, and pharmacology expertise. Rational checkpoint-based design should improve therapeutic index and clinical success.

Limitations: This is a review, not a primary study; no new experimental data or meta-analysis. - Few polymer NP formulations have reached the market or late-stage clinical trials. - The EPR effect has been recently reconsidered; only a small percentage of administered NPs may reach solid tumors. - Active targeting has shown limited clinical translation due to endosomal trapping, tumor heterogeneity, and added regulatory/cost burdens. - In vitro results often fail to predict in vivo behavior. - Long-term toxicity, immunogenicity, and chronic administration safety remain insufficiently defined. - Large-scale manufacturing and reproducible GMP production are not the main focus but are noted as important translation barriers.